


# NEWSFLASH



University of  
Nottingham  
UK | CHINA | MALAYSIA



## CerebroVascular Disease-Cognition phase-2 trial in non-lacunar ischaemic stroke with cerebral small vessel disease

**We're pleased to share that the study has now received IRAS approval and ISCTRN registration. We are currently circulating LIPs to participating sites.**

**We welcome interest from any additional sites who would like to join – please contact us if you would like to get involved: CVD-Cog@nottingham.ac.uk.**



**Our study website is now live, please visit for more information on the study: <https://stroke.nottingham.ac.uk/cvd-cog/>**

## Trial Summary

**PURPOSE:** The purpose of CVD-COG is to investigate whether isosorbide mononitrate and/or cilostazol are effective in treating cSVD in patients who have had non-lacunar ischaemic stroke.

**PARTICIPANTS:** 400 participants will be recruited from 25 UK sites. Participants must be 7 days from diagnosis with a non-lacunar ischaemic stroke or TIA.

**INTERVENTION:** Participants not taking an oral anti-coagulant will be randomly assigned to one of four treatment groups: Cilostazol only; isosorbide mononitrate only; both cilostazol and isosorbide mononitrate; or neither cilostazol nor isosorbide mononitrate.

Participants on an oral anti-coagulant will be randomised to isosorbide mononitrate or no isosorbide mononitrate.

**FOLLOW UP:** Participants will be treated and followed for 6 months. The trial is funded for 3 years by Alzheimer's Society.

Follow our progress on  @CVDCog

If you have any questions please get in touch:



CVD-Cog@nottingham.ac.uk